| Followers | 59 |
| Posts | 7593 |
| Boards Moderated | 0 |
| Alias Born | 10/20/2014 |
Monday, February 21, 2022 8:04:18 AM
Lizzy241/BobWayne, Agree 100% on your insights here!
One hopes that Denner understands the importance of getting
AMRN acquired by BP as quickly as possible so that BP can get
in position to right the ship and rev up the sales engine.
AMRN has messed up almost every opportunity they have had to
salvage their position. With each poor decision comes negative
consequences for the company which management takes no meaningful
responsibility for creating. As much as I hope KM will be able
salvage the situation, so far I do not see it. KM's talks in what
to me seem empty platitudes with no substance behind his plans.
Horrific to see such a great drug demonized by certain interests
without being aggressively defended by the company. Horrific not
just from the shareholders losses but the continued lack of understanding
about the benefits of Vascepa to CVD patients and their doctors.
The public today, and their doctors seem to have no faith in credible
scientific information regarding the drugs effectiveness. Seems that
any positive message is always muddled with old, incorrect, and disproven
propaganda from idiots like Nissen. The sooner a BP such as JNJ or PFE
takes the helm, the sooner these idiotic notions will be laid to rest!
One hopes that Denner understands the importance of getting
AMRN acquired by BP as quickly as possible so that BP can get
in position to right the ship and rev up the sales engine.
AMRN has messed up almost every opportunity they have had to
salvage their position. With each poor decision comes negative
consequences for the company which management takes no meaningful
responsibility for creating. As much as I hope KM will be able
salvage the situation, so far I do not see it. KM's talks in what
to me seem empty platitudes with no substance behind his plans.
Horrific to see such a great drug demonized by certain interests
without being aggressively defended by the company. Horrific not
just from the shareholders losses but the continued lack of understanding
about the benefits of Vascepa to CVD patients and their doctors.
The public today, and their doctors seem to have no faith in credible
scientific information regarding the drugs effectiveness. Seems that
any positive message is always muddled with old, incorrect, and disproven
propaganda from idiots like Nissen. The sooner a BP such as JNJ or PFE
takes the helm, the sooner these idiotic notions will be laid to rest!
Recent AMRN News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/22/2026 09:00:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:02 PM
- Amarin to Report First Quarter 2026 Financial Results and Host Conference Call on April 29, 2026 • GlobeNewswire Inc. • 04/15/2026 12:00:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/10/2026 09:01:34 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/10/2026 09:00:20 PM
- American College of Cardiology (ACC) Scientific Sessions 2026 Underscore the Need for Complementary Therapies Including Icosapent Ethyl (IPE) in Treatment of Elevated Triglycerides and Cardiovascular Risk Reduction • GlobeNewswire Inc. • 04/08/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 08:30:11 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 03/30/2026 09:57:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/27/2026 09:00:07 PM
- Amarin Highlights Guideline Recommended Role of Icosapent Ethyl in Managing Cardiovascular Risk Following Release of Updated 2026 ACC/AHA/Multisociety Dyslipidemia Guideline • GlobeNewswire Inc. • 03/18/2026 12:30:00 PM
- New REDUCE-IT Data in Patients at Extreme Cardiovascular Risk and In Vitro Research on the Mechanistic Effects of Eicosapentaenoic Acid (EPA) on Lipoprotein(a) [Lp(a)] Oxidation to be Presented at the American College of Cardiology’s (ACC) Annual Scienti • GlobeNewswire Inc. • 03/16/2026 12:15:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/02/2026 10:31:01 PM
- Effects of Icosapent Ethyl on Risk and Duration of Hospitalizations and Death in REDUCE-IT® Post Hoc Analysis Published in the European Journal of Preventive Cardiology • GlobeNewswire Inc. • 03/02/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 12:05:26 PM
- Amarin Reports Fourth Quarter and Full Year 2025 Financial Results • GlobeNewswire Inc. • 02/25/2026 12:00:00 PM
- This American Heart Month Amarin Spotlights the Need to Prioritize Proven Widely Available Yet Underutilized Therapies in the Battle Against Cardiovascular Disease • GlobeNewswire Inc. • 02/23/2026 01:00:00 PM
- Amarin to Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on February 25, 2026 • GlobeNewswire Inc. • 02/11/2026 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:09 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:07 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:06 AM
